Macquarie Group LTD Cardiff Oncology, Inc. Call Options Transaction History
Macquarie Group LTD
- $86.4 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CRDF
# of Institutions
125Shares Held
25.3MCall Options Held
866KPut Options Held
203K-
Commodore Capital LP New York, NY5.38MShares$25.6 Million2.34% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$12.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.28MShares$10.9 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.54MShares$7.31 Million0.18% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.44MShares$6.85 Million3.38% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $206M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...